1. Home
  2. CYTK vs HSIC Comparison

CYTK vs HSIC Comparison

Compare CYTK & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$59.89

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Logo Henry Schein Inc.

HSIC

Henry Schein Inc.

N/A

Current Price

$75.16

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CYTK
HSIC
Founded
1997
1932
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
9.6B
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
CYTK
HSIC
Price
$59.89
$75.16
Analyst Decision
Strong Buy
Buy
Analyst Count
18
14
Target Price
$87.56
$84.50
AVG Volume (30 Days)
1.7M
1.5M
Earning Date
05-25-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.21
EPS
N/A
3.27
Revenue
$13,368,000.00
$13,201,995,000.00
Revenue This Year
$9.79
$6.15
Revenue Next Year
$302.66
$3.62
P/E Ratio
N/A
$23.39
Revenue Growth
N/A
5.94
52 Week Low
$29.31
$60.56
52 Week High
$70.98
$89.29

Technical Indicators

Market Signals
Indicator
CYTK
HSIC
Relative Strength Index (RSI) 40.30 39.23
Support Level $59.25 $74.66
Resistance Level $65.93 $79.37
Average True Range (ATR) 2.65 2.50
MACD -0.32 -0.72
Stochastic Oscillator 3.98 5.59

Price Performance

Historical Comparison
CYTK
HSIC

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.

Share on Social Networks: